sofosbuvir has been researched along with Adverse Drug Event in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 28 (82.35) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Wang, L; Xie, W; Zhou, Y; Zhu, X | 1 |
| Hampejskova, L; Hasnain, A; Shah, S | 1 |
| El-Marakby, MG; Sabri, NA; Solayman, MH | 1 |
| Hsin, YH; Huang, CW; Ko, CY; Tsai, QZ; Tsai, YC; Yu, ML | 1 |
| Abdelaty, LN; Elnaggar, AA; Hussein, RRS; Said, AA | 1 |
| Burden, AM; Burkard, T; Hayes, KN; Tadrous, M; Weiler, S | 1 |
| Ammirati, SR; Darnell, TA; Hartis, CE; Johnson, SW; Morgan, MR; Priest, DH; Schmidlin, HN; Silwal, A; Weber, SF | 1 |
| Chen, DS; Chen, PJ; Chen, YS; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Wang, SS; Yang, HC | 1 |
| Crutcher, EL; Greene, EM; Lenz, DU | 1 |
| Beumont, M; Corregidor, AM; Feld, JJ; Felizarta, F; Gamil, M; Ghalib, R; Kakuda, TN; Khalid, O; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Smith, WB; Sulkowski, MS; Van Eygen, V; Van Remoortere, P; Vijgen, L | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Attia, D; Ayoub, H; El Sheemy, RY; El-Khayat, HR; El-Sayed, MH; El-Shabrawi, M; Fouad, YM; Kamal, EM; Maher, M; RizK, A | 1 |
| Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C | 1 |
| Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH | 1 |
| Abdel-Razek, W; Brainard, DM; Doss, W; Elbasiony, M; Elsharkawy, A; Esmat, G; Fouad, R; Hammad, R; Hassany, M; Kersey, K; Lu, S; Massetto, B; McHutchison, JG; Osinusi, A; Shiha, G; Soliman, R; Waked, I; Zakareya, T | 1 |
| Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM | 1 |
| Abdelaziz, A; Abdelmoniem, R; Doss, W; El-Serafy, M; Elakel, W; Esmat, G; Gamal Eldeen, H; Kaddah, M; Medhat, E; Mehrez, M; Yosry, A; Zayed, N | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Deng, H; Fan, X; Han, Q; Li, N; Liu, Z; Wang, X; Wang, Y; Zhang, K; Zhang, X | 1 |
| Asselah, T; Bourgeois, S; Brainard, DM; Davis, MN; Huang, KC; Lai, CL; Mathurin, P; McNally, J; Nguyen, MH; Osinusi, A; Shafran, SD; Shaikh, OS; Svarovskaia, E; Tran, TT; Willems, B | 1 |
| Berrey, MM; Cornpropst, MT; Denning, J; Gao, B; Lawitz, EJ; Mathias, A; Mo, H; Rodriguez-Torres, M; Symonds, WT | 1 |
| Chang, H; Han, Q; Li, N; Liu, X; Liu, Z; Lv, Y; Wang, Y; Zhang, G; Zhu, Q | 1 |
| Brainard, D; Dvory-Sobol, H; Gao, B; Garrison, KL; Genda, T; Hino, K; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, S; McHutchison, JG; Mizokami, M; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Nishiguchi, S; Omata, M; Omote, M; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Botta, D; Coilly, A; D'Alteroche, L; Diallo, A; Duclos-Vallee, JC; Dumortier, J; Durand, F; Fougerou-Leurent, C; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Pageaux, GP; Petrov-Sanchez, V; Radenne, S; Sebagh, M; Silvain, C | 1 |
| Abecassis, MM; Brooks, H; Grant, JL; Hawkins, C; Koppe, SW; Palella, FJ; Stosor, V | 1 |
| Ahn, SH; Brainard, DM; Byun, KS; Han, KH; Han, L; Han, SY; Heo, J; Jeong, SH; Kim, JH; Kim, YJ; Kim, YS; Knox, SJ; Lee, KS; Lee, YJ; Lim, YS; Mathias, A; Mo, H; Paik, SW; Tak, WY; Yang, JC; Yim, HJ; Yoon, SK | 1 |
| Fischler, B; Priftakis, P; Sundin, M | 1 |
| Arias, A; Baños, I; Benítez-Gutiérrez, L; Citores, MJ; Cuervas-Mons, V; de Mendoza, C; Duca, A; Requena, S; Treviño, A | 1 |
| Beets, G; Beumont, M; Gutierrez, JA; Jacquemyn, B; Kakuda, TN; Lawitz, E; Luo, D; Ouwerkerk-Mahadevan, S; Picchio, G; Poordad, F; Van Eygen, V; Van Remoortere, P; Vandevoorde, A; Vijgen, L | 1 |
| Acharya, SK; Chowdhury, A; Doehle, B; Duseja, A; Jiang, D; Kanwar, B; Kapoor, D; Kersey, K; Koshy, A; Madan, K; Mehta, R; Nijhawan, S; Pawan, R; Prasad, M; Sarin, S; Shah, SR; Shukla, A; Sood, A; Subramanian, M; Sud, R; Svarovskaia, E | 1 |
| Boucher, E; Chapman, W; Cheslock, P; Chung, RT; Curry, MP; Mantry, P; Molrine, DC; Schiano, TD; Smith, HL; Wang, Y | 1 |
| Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A | 1 |
| Akremi, R; Allegre, T; Antonini, T; Aumaitre, H; Batisse, D; Bennai, Y; Billaud, E; Chas, J; Dabis, F; De Ledinghen, V; De Truchis, P; Dhiver, C; Dominguez, S; Fedchuk, L; Filipovics, A; Fontaine, H; Harent, S; Lacombe, K; Lafeuillade, A; Leroy, V; Metivier, S; Miailhes, P; Pageaux, GP; Perre, P; Rosenthal, E; Salmon Ceron, D; Sogni, P; Valantin, MA; Zhao, Y | 1 |
2 review(s) available for sofosbuvir and Adverse Drug Event
| Article | Year |
|---|---|
Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study.
Topics: Anilides; Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Recurrence; Ribavirin; Ritonavir; Sofosbuvir; Sustained Virologic Response | 2023 |
Efficacy and safety of sofosbuvir-based therapy for the treatment of chronic hepatitis C in treatment-naïve and treatment-experienced patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C, Chronic; Humans; Middle Aged; Recurrence; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
11 trial(s) available for sofosbuvir and Adverse Drug Event
| Article | Year |
|---|---|
Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Young Adult | 2018 |
Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population.
Topics: Adult; Aged; Anemia; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Neutropenia; Pancytopenia; Ribavirin; Sofosbuvir; Thrombocytopenia; Treatment Outcome | 2018 |
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2019 |
Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection.
Topics: Antiviral Agents; Carbamates; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Placebos; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear).
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Load; Young Adult | 2013 |
Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial.
Topics: Adult; Aged; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Young Adult | 2014 |
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation.
Topics: Antiviral Agents; Belgium; Carbamates; Cholestasis; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C; Humans; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2015 |
A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Young Adult | 2016 |
Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug-Related Side Effects and Adverse Reactions; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Simeprevir; Sofosbuvir; Treatment Outcome; United States; Valine | 2017 |
Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; India; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2017 |
21 other study(ies) available for sofosbuvir and Adverse Drug Event
| Article | Year |
|---|---|
Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System.
Topics: Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmacovigilance; Sofosbuvir | 2023 |
Visual symptoms with Sofosbuvir in hepatitis C treatment - a case report from Pakistan.
Topics: Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pakistan; Sofosbuvir; Treatment Outcome | 2023 |
Treatment effectiveness and side effects of patients with hepatitis C in the prisons of Southern Taiwan: a real-life retrospective analysis.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prisons; Retrospective Studies; Sofosbuvir; Taiwan; Treatment Outcome | 2023 |
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Random Allocation; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase.
Topics: Antiviral Agents; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; World Health Organization | 2021 |
Effectiveness of ledipasvir/sofosbuvir in real-world patients with chronic hepatitis C: a collaborative treatment approach.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Young Adult | 2017 |
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Heart Transplantation; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Young Adult | 2018 |
Sexual Dysfunction in a Patient Taking Ledipasvir/Sofosbuvir for the Treatment of Hepatitis C: A Case Report.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Fluorenes; Hepatitis C; Humans; Male; Sexual Dysfunction, Physiological; Sofosbuvir; Uridine Monophosphate | 2019 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2018 |
Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Argentina; Carbamates; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Treatment Outcome; Valine | 2019 |
Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Recurrence; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Young Adult | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
High sustained virologic response rates of sofosbuvir-based regimens in Chinese patients with HCV genotype 3a infection in a real-world setting.
Topics: Adult; Antiviral Agents; Asian People; China; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response | 2019 |
Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Coinfection; Drug-Related Side Effects and Adverse Reactions; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; Prospective Studies; Recurrence; Sofosbuvir; Transplant Recipients; Treatment Outcome; Viral Load | 2016 |
Sofosbuvir and Simeprevir Treatment of a Stem Cell Transplanted Teenager With Chronic Hepatitis C Infection.
Topics: Adolescent; Anemia, Sickle Cell; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Edema; Hepatitis C, Chronic; Humans; Male; Protease Inhibitors; Simeprevir; Sofosbuvir; Stem Cell Transplantation; Sustained Virologic Response; Transplant Recipients | 2016 |
Drug-Induced Lung Injury in a Liver Transplant Patient Treated With Sofosbuvir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Liver Transplantation; Lung Injury; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
Topics: Allografts; Antibodies, Monoclonal; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Liver Transplantation; Male; Middle Aged; Oligopeptides; Proof of Concept Study; RNA, Viral; Secondary Prevention; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome | 2017 |
Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; HIV Infections; Humans; Italy; Male; Middle Aged; Protease Inhibitors; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug-Related Side Effects and Adverse Reactions; Female; France; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |